Akebia Therapeutics Stock Price. Everything You Need To Know About The Akebia Therapeutics Stock!
Akebia Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that specializes in the development and commercialization of therapeutics for patients with kidney diseases. With 204 full-time employees, the company went public on 2014-03-20 and is focused on developing and commercializing therapeutics that serve as a foundation for future growth.
The firm’s portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is an orally administered tablet that controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease (DD-CKD) or hyperphosphatemia indication and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD) in adult patients.
Akebia Therapeutics, Inc. utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers. By researching Akebia Therapeutics, Inc. and its portfolio, including Auryxia and Vafseo, investors and professionals can stay informed about the latest developments in the biopharmaceutical industry. While it is important to stay up-to-date with the latest trends, such as the company’s stock price, shares, and market cap, it is also essential to seek professional advice before making any investment decisions. Akebia Therapeutics, Inc. is a biopharmaceutical company that offers innovative solutions to support the treatment of kidney diseases, making it a company worth considering for those interested in investing in the industry.
Akebia Therapeutics Stock Price. Everything You Need To Know About The Akebia Therapeutics Stock! performance
- Employees 204
- Company HQ Cambridge
- Website https://akebia.com/
- AKBA Asset Type Common Stock
- AKBA Market Capitalization 286.8M
- Earnings Per Share -0.28
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you an investor from Malaysia, Thailand, Indonesia, or Vietnam looking to expand your stock portfolio? Look no further than Akebia Therapeutics. As a content marketing expert at Zorion, we understand the importance of providing valuable insights and recommendations to retail investors in Southeast Asia. Akebia Therapeutics is an innovative biopharmaceutical company that focuses on developing therapies for kidney diseases and other critical ailments. With its groundbreaking research and development efforts, Akebia Therapeutics has gained significant attention in the healthcare sector. By investing in Akebia Therapeutics, you can be part of its mission to improve patients’ lives and make a lasting impact. Whether you’re an experienced investor or just starting, Zorion offers you the resources and educational materials to make informed investment decisions. Don’t miss out on the opportunity to invest in Akebia Therapeutics and make a difference in the healthcare industry. Start investing today!
